Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Healthcare Shares
Cochlear share price lower on acquisition update
Share Market News
5 things to watch on the ASX 200 on Friday
Broker Notes
'Dual tailwinds': 2 quality ASX 200 shares to buy for long-term wealth
Growth Shares
ASX growth shares could be primed for a rally. Is it time to jump back in?
Dividend Investing
4 things to look for when buying ASX dividend stocks
Broker Notes
Brokers say these high-quality ASX 50 shares are buys
Blue Chip Shares
Strengthen your portfolio with these ASX 200 blue chip shares
Broker Notes
Brokers say these ASX 100 shares are buys right now
Blue Chip Shares
Here are 3 ASX 200 blue chip shares that analysts love
Growth Shares
Here are 2 outstanding ASX 200 growth shares brokers rate as buys
Growth Shares
'Under the radar success': 3 quality ASX 200 growth shares to buy right now
Share Market News
5 things to watch on the ASX 200 on Friday
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
